Evaluación de actividad física como coadyuvante terapéutico para pacientes con enfermedad inflamatoria intestinal: una revisión.

Author:

Fernández-Lázaro Diego1ORCID,Hernández-Burgos Nuria2ORCID,Cobreros Mielgo Raúl3ORCID,García-Lázaro Sandra4ORCID

Affiliation:

1. Departamento de Biología Celular, Genética, Histología y Farmacología, Facultad de Ciencias de la Salud, Universidad de Valladolid, Campus de Soria, 42003 Soria, España. Grupo de Investigación en Neurobiología, Facultad de Medicina, Universidad de Valladolid, Valladolid, España.

2. Departamento de Biología Celular, Genética, Histología y Farmacología, Facultad de Ciencias de la Salud, Universidad de Valladolid, Campus de Soria, 42003 Soria, España. Servicio de Medicina Interna, Hospital Enrest Luch Martín, Calatayud, España.

3. Departamento de Fisioterapia, Instituto de Biomedicina (IBIOMED), Universidad de León, Campus de Vegazana, León, España.

4. Departamento de Fisioterapia, Facultad de Ciencias de la Salud, Universidad de Valladolid, Campus de Soria, Soria, España.

Abstract

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). Pharmacological treatment in IBD presents a loss of efficacy and side effects, inviting to consider alternative strategies, such as the practice of physical activity (PA), as a therapeutic adjuvant. The purpose of this review was to evaluate the effectiveness of PA interventions as a tool to in-crease physical fitness, and health-related quality of life (HRQoL) and improve the symptomatology in patients with CD and UC, identifying the optimal PA component. The review was performed, by searching the electronic databases Medline (PubMed), SciELO, and Cochrane Library Plus, including randomized controlled trials from the last 10 years that related to IBD and PA, until January 31, 2022. We found four studies with a total of 133 patients. The performance of PA in patients with IBD (UC and CD) increases (p>0.05) physical capacity, skeletal muscle mass, bone mineral density, and HRQoL, significantly (p<0.05) increasing mood. In addition, it significantly (p<0.05) decreases intestinal in-flammation and extraintestinal manifestations. A trend of reduction (p>0.05) of fatigue, blood pressure, and microbiota restoration was observed. Moderate PA and performed regularly for a minimum of eight weeks, favors the improve-ment of the IBD patient at the physical, psychological, HRQoL, and symptom-atology levels.

Publisher

Universidad del Zulia

Subject

General Medicine

Reference61 articles.

1. Oviedo C, Yañez M, Pennacchiotti V. Frequency of oral manifestation in pa-tients with inflammatory bowel disea-se in Chile. Int J Odontostomatol 2017; 11: 267–271. Disponible en: https://www.scielo.cl/scielo.php?script=sci_abstract&pid=S0718-381X2017000300267&lng=en&nrm=iso#:~:text=Of%20these% 20patients%2C%2037%2 0%25%20presented,recurrent%20oral%20ulcer%20(ROU).

2. Meligrana N, Quera R, Figueroa C, Ibá-ñez P, Lubascher J, Kronberg U. Facto-res ambientales en el desarrollo y evo-lución de la enfermedad inflamatoria intestinal. Rev Med Chile 2019; 147: 212–220. Disponible en: https://www.scielo.cl/scielo.php?pid=S0034-9887 2019000200212&script=sci_artt ext&tlng=en

3. World Gastroenterology Organization (WGO). Practice Guideline Inflammatory bowel disease (IBD). World Gastroentero-logy Organisation [Internet] 2022 [citado, 2022 febrero 10] Disponible en: https://www.worldgastroenterology.org/guideli-nes/global-guidelines/inflammatory-bowel-disease-ibd.

4. Yamamoto-Furusho JK, Bosques-Padilla FJ, Charúa-Guindic L, Cortés-Espinosa T, Miranda-Cordero RM, Saez A, Ledesma I.Inflammatory bowel disease in Mexico: epi-demiology, burden of disease, and treatment trends. Rev Gastroenterol México 2020; 85: 246–256. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32143974/.

5. The European Federation of Crohn’s & ulcerative colitis associations (EFCCA). What is inflammatory bowel disease? Euro-pean Federation of Crohn’s & ulcerative co-litis associations 2022 [Internet] [citado, 2022 febrero 10] Disponible en: https://www.efcca.org/en/what-ibd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3